Use of multiple biomarkers for a molecular diagnosis of prostate cancer

Landers, Kelly A., Burger, Michelle J., Tebay, Michelle A., Purdie, David M., Scells, Betty, Samaratunga, Hemamali, Lavin, Martin F. and Gardiner, Robert A. (2005) Use of multiple biomarkers for a molecular diagnosis of prostate cancer. International Journal of Cancer, 114 6: 950-956. doi:10.1002/ijc.20760


Author Landers, Kelly A.
Burger, Michelle J.
Tebay, Michelle A.
Purdie, David M.
Scells, Betty
Samaratunga, Hemamali
Lavin, Martin F.
Gardiner, Robert A.
Title Use of multiple biomarkers for a molecular diagnosis of prostate cancer
Journal name International Journal of Cancer   Check publisher's open access policy
ISSN 0020-7136
Publication date 2005-05-10
Year available 2004
Sub-type Article (original research)
DOI 10.1002/ijc.20760
Open Access Status Not yet assessed
Volume 114
Issue 6
Start page 950
End page 956
Total pages 7
Editor H. zur Hausen
Place of publication Hoboken, U.S.A.
Publisher John Wiley & Sons Inc.
Language eng
Subject C1
321012 Nephrology and Urology
730115 Urogenital system and disorders
Abstract The identification of biomarkers capable of providing a reliable molecular diagnostic test for prostate cancer (PCa) is highly desirabie clinically. We describe here 4 biomarkers, UDP-N-Acetyl-alpha-D-galactosamine transferase (GalNAc-T3; not previously associated with PCa), PSMA, Hepsin and DD3/PCA3, which, in combination, distinguish prostate cancer from benign prostate hyperplasia (BPH). GalNAc-T3 was identified as overexpressed in PCa tissues by microarray analysis, confirmed by quantitative real-time PCR and shown immunohistochemically to be localised to prostate epithelial cells with higher expression in malignant cells. Real-time quantitative PCR analysis across 21 PCa and 34 BPH tissues showed 4.6-fold overexpression of GalNAc-T3 (p = 0.005). The noncoding mRNA (DD3/PCA3) was overexpressed 140-fold (p = 0.007) in the cancer samples compared to BPH tissues. Hepsin was overexpressed 21-fold (p = 0.049, whereas the overexpression for PSMA was 66-fold (p = 0.047). When the gene expression data for these 4 biomarkers was combined in a logistic regression model, a predictive index was obtained that distinguished 100% of the PCa samples from all of the BPH samples. Therefore, combining these genes in a real-time PCR assay represents a powerful new approach to diagnosing PCa by molecular profiling. (c) 2005 Wiley-Liss, Inc.
Keyword Oncology
Diagnosis
Prostate Cancer
Psma
Dd3/pca3
Hepsin
Multivariate Analysis
Alpha-d-galactosamine
N-acetylgalactosaminyl Transferase-3
Endothelial Growth-factor
Membrane Antigen
Gene-expression
Biochemical Recurrence
Cells
Cloning
Adenocarcinoma
Protease
Q-Index Code C1
Institutional Status UQ
Additional Notes Published Online: 17 Dec 2004

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
2006 Higher Education Research Data Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 84 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 95 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 15:26:45 EST